×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Agreement to acquire TESARO
GSK
On 3 December 2018 we announced our agreement to acquire TESARO, an oncology-focused company based in the US for approximately $5.1bn.
36 months ago
GSK avoids paying larger share of Zejula sales to AstraZeneca with UK appeals court win
Fierce Pharma
It appears GSK won't have to fork over extra Zejula royalties to AstraZeneca after all, thanks to an appeals court victory in the companies'...
3 months ago
GSK gets appeal go-ahead in licensing clash with AZ
Life Sciences Intellectual Property Review
MAXSHOT.PL / Shutterstock.com. 13 February 2024Big PharmaLiz Hockley. GSK gets appeal go-ahead in licensing clash with AZ.
3 months ago
Tesaro (TSRO) in Focus: Stock Adds 8.6% in Session
Yahoo News Singapore
Tesaro, Inc. (TSRO) shares rose almost 9% in the last trading session.
2 weeks ago
GSK's Tesaro wins latest round in AstraZeneca dispute
The Pharma Letter
The UK's Court of Appeal ruled in favor of Tesaro in a row over whether royalties were applicable to all Zejula sales, or restricted to the...
3 months ago
Why Tesaro Shares Vaulted Higher
AOL.com
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material...
3 weeks ago
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GSK
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company ... The proposed transaction will significantly strengthen...
65 months ago
Jemperli (dostarlimab-gxly) to Treat Advanced Solid Tumours
Clinical Trials Arena
Jemperli (dostarlimab-gxly) is an anti-PD-1 antibody indicated to treat dMMR solid tumours and dMMR endometrial cancer in adults.
7 months ago
Insilico Medicine appoints Keith Mikule, Ph.D. as VP of Business Development
EurekAlert!
Mikule is an accomplished scientist with 18 years of drug development expertise who previously served as Head of Business Development and...
2 months ago
Tesaro (TSRO) Reports Q3 Loss, Lags Revenue Estimates
Yahoo News New Zealand
Tesaro (TSRO) delivered earnings and revenue surprises of 4.96% and -7.36%, respectively, for the quarter ended September 2018.
2 weeks ago